AboutJayme Zage, PhD

As a senior leader of Sg2’s service line research team, Jayme supports client needs across a broad range of service line initiatives, including structuring, strategic planning and workforce alignment. She is an esteemed thought leader in the neurosciences and behavioral health. While working on-site with clients, she often leads behavioral health assessments to help prioritize program development and investment in these critical services.

During her 14-year tenure within Sg2’s intelligence delivery team, Jayme has developed the initial content for many service lines and topic areas, including the neurosciences, women’s health, surgical services, inpatient rehab and behavioral health. She is also a seasoned speaker regularly appearing in Sg2’s Executive Summit conference series. She has been invited to speak at national conferences on both neurosciences and behavioral health topics.

Before joining Sg2, Jayme worked with Technomic International’s pharmaceutical group and Abbott Laboratories’ drug-coated stent program. These experiences extended her field of expertise to include drug development, marketing and regulatory issues.

As a part of her doctoral work at Columbia University, Jayme studied and researched the molecular mechanism of disease. Her examination of basic cellular function can be applied to numerous diseases, including diabetes, Alzheimer disease, viral and bacterial infections, and cystic fibrosis.

Jayme remained at Columbia University as a National Institutes of Health–funded postdoctoral fellow to research the function of neuronal proteins—molecules implicated in numerous diseases. In her postdoctoral training at the University of Chicago, she examined the role of presenilin in Alzheimer disease. Jayme has a BS in chemistry from the Colorado School of Mines.

"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube